

Correction: Tissue biodistribution and tumor targeting of near-infrared labelled anti-CD38 antibody-drug conjugate in preclinical multiple myeloma

Nicholas Cho^{1,2}, Sooah Ko² and Monica Shokeen^{1,2,3}

¹Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA

²Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, MO, USA

³Alvin J. Siteman Cancer Center, Washington University School of Medicine and Barnes-Jewish Hospital, St. Louis, MO, USA

Published: April 11, 2025

Copyright: © 2025 Cho et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: Oncotarget’s investigation of the paper is now complete. We’ve determined that in Figure 3A, the Day 0 representative image of MM.1S SQ mice in the “DARA-IR” group was unintentionally duplicated from the Day 2 image, taken before the fluorescent imaging. This error happened during the figure assembly process. The authors have removed the Day 0 images for both groups of mice. As stated in the Figure 3A caption, the figure is intended to show mice at days 2 and 9 post-dye administration. The authors declare that these modifications to the figures do not change the results or conclusions of the paper.

Original article: Oncotarget. 2021; 12:2039–2050. <https://doi.org/10.18632/oncotarget.28074>




Figure 3: High contrast observed with DARA-DM1-IR at longer time points in MM.1S SQ mice. (A) Representative IRDye800 in vivo images of MM.1S SQ mice 2 and 9 days post administration of DARA-DM1-IR and DARA-IR. (B) Plot of calculated Tumor to Background Ratios (TBRs) in MM.1S SQ mice across individual time points following administration of DARA-DM1-IR and DARA-IR. Background is defined as the non-tumor, contralateral left flank of the mouse. Repeated measures two-way ANOVA followed by Sidak's multiple comparison's test was performed on TBR data. $n = 3-4$ /group. (C) Normalized biodistribution (defined as tissue to muscle ratio (TMR)) of DARA-DM1-IR 2, 7 and 9 days after administration of fluorescent conjugate. $n = 3-4$ /group. Two-way ANOVA followed by Sidak's multiple comparisons test was performed on biodistribution data. (D) Immunohistochemistry of excised tumor sections from mice injected with DARA-DM1-IR and DARA-IR. Nuclear stain was performed with Hoechst 33342. Magnification: 40 \times ; Scale bar: 100 μ m. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.0001$. Error bars represent standard deviation.